Effect of glycyrrhizin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes

Xenobiotica

Volumn 40, Issue 6, 2010, Pages 393-399

  Tu, J H ^a   Hu, D L ^a   Dai, L L ^a   Sun, Y ^b   Fan, L ^a   Zhang, M ^a   Tan, Z R ^a   Chen, Y ^a   Li, Z ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP3A4; Glycyrrhizin; Induction; Omeprazole; Pharmacokinetics

Indexed keywords

5 HYDROXYOMEPRAZOLE; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; DRUG METABOLITE; GLYCYRRHIZIC ACID; OMEPRAZOLE; OMEPRAZOLE SULFONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOCATALYSIS; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HYDROXYLATION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SULFOXIDATION;

ANTI-INFLAMMATORY AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; GENOTYPE; GLYCYRRHIZIC ACID; HUMANS; HYDROXYLATION; MALE; OMEPRAZOLE; YOUNG ADULT;

EID: 77952272801     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498251003748095     Document Type: Article

References (32)

1. Adamsson I, Edlund C, Nord CE. (2000). Microbial ecology and treatment of Helicobacter pylori infections: review. J Chemother 12: 5-16.
2. Andersson T, Miners JO, Veronese ME, Birkett DJ. (1994). Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol 37: 597-604.
3. Andersson T, Miners JO, Veronese ME, Tassaneeyakul W, Tassaneeyakul W, Meyer UA, Birkett DJ. (1993). Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 36: 521-530.
4. Cederberg C, Andersson T, Ska®nberg I. (1989). Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl 166: 33-40; discussion 41.
5. Chang M, Tybring G, Dahl ML, Götharson E, Sagar M, Seensalu R, Bertilsson L. (1995). Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39: 511-518.
6. Chang TK, Waxman DJ. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38: 51-73.
7. Chen Y, Goldstein JA. (2009). The transcriptional regulation of the human CYP2C genes. Curr Drug Metab 10: 567-578.
8. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. (1994a). The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422.
9. de Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. (1994b). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598. (Pubitemid 24334747)
10. de Morais SM, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, Xiao ZS, Ile N, Zhou HH. (1995). Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 58: 404-411.
11. Fujisawa K, Watanabe Y, Kimura K. (1980). Therapeutic approach to chronic active hepatitis with glycyrrhizin. Asian Med J 23: 754.
12. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, Hanai H, Kubota T, Ishizaki T, Kaneko E. (1998). Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 129: 1027-1030.
13. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. (2005). Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 20: 153-167.
14. González HM, Romero EM, Chavez Tde J, Peregrina AA, Quezada V, Hoyo-Vadillo C. (2002). Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction. J Chromatogr B Analyt Technol Biomed Life Sci 780: 459-465.
15. Handschin C, Meyer UA. (2003). Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55: 649-673.
16. Hattori T, Ikematsu S, Koito A, Matsushita S, Maeda Y, Hada M, Fujimaki M, Takatsuki K. (1989). Preliminary evidence for inhibitory effect of glycyrrhizin on HIV replication in patients with AIDS. Antiviral Res 11: 255-261.
17. He JX, Akao T, Nishino T, Tani T. (2001). The influence of commonly prescribed synthetic drugs for peptic ulcer on the pharmacokinetic fate of glycyrrhizin from Shaoyao-Gancao-tang. Biol Pharm Bull 24: 1395-1399.
18. Jeong HG, You HJ, Park SJ, Moon AR, Chung YC, Kang SK, Chun HK. (2002). Hepatoprotective effects of 18beta-glycyrrhetinic acid on carbon tetrachloride-induced liver injury: inhibition of cytochrome P450 2E1 expression. Pharmacol Res 46: 221-227.
19. Mu Y, Zhang J, Zhang S, Zhou HH, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. (2006). Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 316: 1369-1377.
20. Paolini M, Pozzetti L, Sapone A, Cantelli-Forti G. (1998). Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 62: 571-582.
21. Paolini M, Barillari J, Broccoli M, Pozzetti L, Perocco P, Cantelli-Forti G. (1999). Effect of liquorice and glycyrrhizin on rat liver carcinogen metabolizing enzymes. Cancer Lett 145: 35-42.
22. Rega®rdh CG. (1986). Pharmacokinetics and metabolism of omeprazole in man. Scand J Gastroenterol Suppl 118: 99-104.
23. Shibata S. (2000). A drug over the millennia: pharmacognosy, chemistry, and pharmacology of licorice. Yakugaku Zasshi 120: 849-862.
24. Shu Y, Wang LS, Xiao WM, Wang W, Huang SL, Zhou HH. (2000). Probing CYP2C19 and CYP3A4 activities in Chinese liver microsomes by quantification of 5-hydroxyomeprazole and omeprazole sulphone. Acta Pharmacol Sin 21: 753-758.
25. Takeda S, Ishthara K, Wakui Y, Amagaya S, Maruno M, Akao T, Kobashi K. (1996). Bioavailability study of glycyrrhetic acid after oral administration of glycyrrhizin in rats; relevance to the intestinal bacterial hydrolysis. J Pharm Pharmacol 48: 902-905.
26. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. (1998). Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 12: 199-205.
27. Veldt BJ, Hansen BE, Ikeda K, Verhey E, Suzuki H, Schalm SW. (2006). Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Scand J Gastroenterol 41: 1087-1094.
28. Wilkinson GR, Guengerich FP, Branch RA. (1989). Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 43: 53-76.
29. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH. (1997). Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 281: 604-609.
30. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. (1997). Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283: 434-442.
31. Yin OQ, Tomlinson B, Waye MM, Chow AH, Chow MS. (2004). Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 14: 841-850.
32. Zhou H-H. (2003). Pharmacogenetics. Beijing: People's Military Medical Press, p. 61-83.